drugset

drugset / Trial / NCT00706498

Phase II Study of BI 2536 in Prostate Cancer

NCT00706498 ↗

Phase 2 Completed 20 enrolled Boehringer Ingelheim

NaSingle-groupTreatment

Summary

A study to investigate the activity of BI 2536 in Prostate Cancer

Timeline

Start: 2006-09
Primary completion: 2008-02
Completion: —

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	BI 2536	Small molecule	200 mg	Intravenous

Indications